» Articles » PMID: 3597377

Multiple Effects of Tumor Necrosis Factor on Lipoprotein Lipase in Vivo

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1987 Jun 15
PMID 3597377
Citations 45
Authors
Affiliations
Soon will be listed here.
Abstract

A single dose of recombinant murine tumor necrosis factor (TNF) suppressed lipoprotein lipase activity in adipose tissue of fed rats, mice, and guinea pigs for 48 h, even though TNF itself is rapidly metabolized in vivo. Immunoprecipitation of [35S]lipoprotein lipase from fat pads pulse-labeled with [35S]methionine showed a decrease in relative synthesis of the enzyme, which correlated to the decrease in activity. There was no decrease in general protein synthesis and no change in distribution of the enzyme between adipocytes and extracellular locations in the tissue. This is in contrast to fasting in which case there is redistribution of the enzyme within the tissue, decrease in general protein synthesis, but no change in relative synthesis of lipoprotein lipase. TNF did not decrease lipoprotein lipase activity in any tissue other than the adipose but increased the activity in several cases, most markedly in the liver. No [35S]methionine was incorporated into lipoprotein lipase by liver slices from normal or TNF-treated animals. Thus, the increased activity can not be ascribed to enhanced hepatic synthesis of the enzyme. There was an increase in lipoprotein lipase activity in plasma, which correlated to the increase in liver. Thus, TNF suppresses lipoprotein lipase synthesis in adipocytes, but not in other tissues, and has some as yet undefined effect on lipoprotein lipase turnover in extrahepatic tissues, which results in increased transport of active lipase through plasma to the liver.

Citing Articles

COVID-19-associated hypertriglyceridemia and impact of treatment.

Kaddoura R, Ibrahim M, Al-Amri M, Nair A, Alharafsheh A, Alyafei S Front Med (Lausanne). 2024; 11:1326156.

PMID: 38449886 PMC: 10915025. DOI: 10.3389/fmed.2024.1326156.


Disturbed lipid profile in common variable immunodeficiency - a pathogenic loop of inflammation and metabolic disturbances.

Jorgensen S, Macpherson M, Skarpengland T, Berge R, Fevang B, Halvorsen B Front Immunol. 2023; 14:1199727.

PMID: 37545531 PMC: 10398391. DOI: 10.3389/fimmu.2023.1199727.


Linkage of Infection to Adverse Systemic Complications: Periodontal Disease, Toll-Like Receptors, and Other Pattern Recognition Systems.

Wallet S, Puri V, Gibson F Vaccines (Basel). 2018; 6(2).

PMID: 29621153 PMC: 6027258. DOI: 10.3390/vaccines6020021.


Novel Insights in Systemic Lupus Erythematosus and Atherosclerosis.

Teixeira V, Tam L Front Med (Lausanne). 2018; 4:262.

PMID: 29435447 PMC: 5796914. DOI: 10.3389/fmed.2017.00262.


Triglyceride Treatment in the Age of Cholesterol Reduction.

Agrawal N, Freitas Corradi P, Gumaste N, Goldberg I Prog Cardiovasc Dis. 2016; 59(2):107-118.

PMID: 27544319 PMC: 5364728. DOI: 10.1016/j.pcad.2016.08.003.